Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in New York state
AuthorsEssock, Susan M.
Covell, Nancy H.
Lieberman, Jeffrey A.
Sederer, Lloyd I.
Finnerty, Molly T.
Frazier, Jean A.
UMass Chan AffiliationsDepartment of Psychiatry
Drug Administration Schedule
Drug Therapy, Combination
Insurance Claim Review
Physician's Practice Patterns
*Quality Assurance, Health Care
MetadataShow full item record
AbstractOBJECTIVE: This study sought to identify and characterize rates of clinically questionable prescribing in New York State. METHODS: As part of a quality improvement initiative, 34 national psychopharmacology experts identified a set of questionable prescribing practices recognizable from pharmacy claims data. Indicators of such practices were applied to Medicaid claims data for 217,216 beneficiaries in New York State who had an active psychotropic prescription on April 1, 2008. RESULTS: A total of 156,103 (72%) of these beneficiaries had one or more continuing (>90 days) prescriptions for a psychotropic. About 10% of adults were prescribed four or more psychotropics concurrently, and 13% of children and 2% of older adults were prescribed three or more concurrently. Prescribing an antipsychotic with a moderate-to-high risk of causing metabolic abnormalities approached 50% (46%) among individuals who had existing cardiometabolic conditions. Among beneficiaries prescribed second-generation antipsychotics with a moderate-to-high risk of causing metabolic abnormalities, over half (60%) had not received a metabolic screening test in the past year. Among women of reproductive age prescribed mood stabilizers, over one-quarter (30%) were prescribed a valproic acid-based formulation despite its potential for teratogenicity. Only 2% of youths under age 18 were prescribed benzodiazepines; however, about half (48%) had trials over 90 days' duration. CONCLUSIONS: Examination of pharmacy claims from Medicaid beneficiaries in New York State indicated that prescribing practices deemed clinically questionable by pharmacology experts are common. Aggregated pharmacy claims data can identify such practices, and reviews of these data can be a core component of efforts to improve prescribing practices.
SourcePsychiatr Serv. 2009 Dec;60(12):1595-602. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/45902
NotesDr. Jean A. Frazier is a member of the New York State Office of Mental Health Scientific Advisory Committee, who served as coauthors.
Related ResourcesLink to Article in PubMed